Literature DB >> 25303296

GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.

Daniel M Kawaguchi1, Stephen J Glatt.   

Abstract

AIM: This study aimed to evaluate the relationship between a human GRIK4 gene polymorphism (rs1954787) and responsiveness to antidepressant treatment in depressed patients.
METHODS: A meta-analysis was carried out on five studies. Pooled odds ratios (ORs), 95% CIs and a χ(2) test measuring heterogeneity were calculated. A test of publication bias was also conducted.
RESULTS: Alleles and genotypes from a total of 2169 depressed patients were analyzed. The results showed that the C allele appeared more frequently than the T allele in responders to treatment (OR: 1.22; 95% CI: 1.035-1.445; z = 2.36; p = 0.018). Similarly, CC homozygotes were more likely than TT homozygotes to respond to treatment (OR: 1.45; 95% CI: 1.107-1.913; z = 2.69; p = 0.007). No evidence of publication bias was detected.
CONCLUSION: Subjects possessing the C allele or CC genotype of the GRIK4 polymorphism rs1954787 are more likely to respond to antidepressant treatment relative to subjects harboring the T allele and TT genotype. Additional replication of this result is required before this association can be considered definitive, after which it may become possible to employ this marker in conjunction with other known predictors in order to anticipate the outcomes of treatment with antidepressant medications.

Entities:  

Keywords:  GRIK4 polymorphism; antidepressant; glutamate; major depressive disorder; meta-analysis; predictor; treatment response

Mesh:

Substances:

Year:  2014        PMID: 25303296      PMCID: PMC4208722          DOI: 10.2217/pgs.14.96

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  19 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.

Authors:  Alessandro Serretti; Alberto Chiesa; Concetta Crisafulli; Isabelle Massat; Sylvie Linotte; Raffaella Calati; Siegfried Kasper; Ursula Bailer; Yves Lecrubier; Martin Fink; Irina Antonijevic; Carlos Forray; Lenore Snyder; Joseph Bollen; Joseph Zohar; Diana De Ronchi; Daniel Souery; Julien Mendlewicz
Journal:  Neuropsychobiology       Date:  2012-01-05       Impact factor: 2.328

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

4.  Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.

Authors:  Silvia Paddock; Gonzalo Laje; Dennis Charney; A John Rush; Alexander F Wilson; Alexa J M Sorant; Robert Lipsky; Stephen R Wisniewski; Husseini Manji; Francis J McMahon
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

7.  Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.

Authors:  Gerard Sanacora; Ralitza Gueorguieva; C Neill Epperson; Yu-Te Wu; Michael Appel; Douglas L Rothman; John H Krystal; Graeme F Mason
Journal:  Arch Gen Psychiatry       Date:  2004-07

8.  AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.

Authors:  Antonio Drago; Ina Giegling; Martin Schäfer; Annette M Hartmann; Marion Friedl; Bettina Konte; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  Eur Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 4.600

9.  Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

Authors:  Mengjia Pu; Zhijun Zhang; Zhi Xu; Yanyan Shi; Leiyu Geng; Yonggui Yuan; Xiangrong Zhang; Gavin P Reynolds
Journal:  Pharmacogenomics       Date:  2013-02       Impact factor: 2.533

10.  Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

Authors: 
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

View more
  10 in total

Review 1.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

2.  Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences.

Authors:  A Sivadas; M Z Salleh; L K Teh; V Scaria
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 3.  Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Bernhard T Baune
Journal:  EPMA J       Date:  2017-09-05       Impact factor: 6.543

Review 4.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

5.  The role of GRIK4 gene in treatment-resistant depression.

Authors:  Elena Milanesi; Cristian Bonvicini; Chiara Congiu; Marco Bortolomasi; Giulio Gainelli; Massimo Gennarelli; Alessandra Minelli
Journal:  Genet Res (Camb)       Date:  2015-07-03       Impact factor: 1.588

6.  Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.

Authors:  Víctor Pérez; Ariana Salavert; Jordi Espadaler; Miquel Tuson; Jerónimo Saiz-Ruiz; Cristina Sáez-Navarro; Julio Bobes; Enrique Baca-García; Eduard Vieta; José M Olivares; Roberto Rodriguez-Jimenez; José M Villagrán; Josep Gascón; Josep Cañete-Crespillo; Montse Solé; Pilar A Saiz; Ángela Ibáñez; Javier de Diego-Adeliño; José M Menchón
Journal:  BMC Psychiatry       Date:  2017-07-14       Impact factor: 3.630

Review 7.  Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.

Authors:  Alfredo B Cuéllar-Barboza; Susan L McElroy; Marin Veldic; Balwinder Singh; Simon Kung; Francisco Romo-Nava; Nicolas A Nunez; Alejandra Cabello-Arreola; Brandon J Coombes; Miguel Prieto; Hannah K Betcher; Katherine M Moore; Stacey J Winham; Joanna M Biernacka; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2020-07-04

8.  GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.

Authors:  Qianqian Sun; Fan Yuan; Ruixue Yuan; Decheng Ren; Yuhao Zhu; Yan Bi; Jiaxin Hu; Zhenming Guo; Fei Xu; Weibo Niu; Gaini Ma; Xi Wu; Fengping Yang; Lu Wang; Xingwang Li; Tao Yu; Lin He; Guang He
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome.

Authors:  Kiran Girdhar; Gabriel E Hoffman; Yan Jiang; Leanne Brown; Marija Kundakovic; Mads E Hauberg; Nancy J Francoeur; Ying-Chih Wang; Hardik Shah; David H Kavanagh; Elizabeth Zharovsky; Rivka Jacobov; Jennifer R Wiseman; Royce Park; Jessica S Johnson; Bibi S Kassim; Laura Sloofman; Eugenio Mattei; Zhiping Weng; Solveig K Sieberts; Mette A Peters; Brent T Harris; Barbara K Lipska; Pamela Sklar; Panos Roussos; Schahram Akbarian
Journal:  Nat Neurosci       Date:  2018-07-23       Impact factor: 24.884

10.  Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness.

Authors:  Tamim Ahsan; Nusrat Jahan Urmi; Abu Ashfaqur Sajib
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.